Literature DB >> 21907738

IMP dehydrogenase deficiency in Leishmania donovani causes a restrictive growth phenotype in promastigotes but is not essential for infection in mice.

Audrey L Fulwiler1, Jan M Boitz, Caslin Gilroy, Phillip A Yates, Armando Jardim, Buddy Ullman.   

Abstract

Leishmania cannot synthesize purines de novo and therefore must scavenge purines from its host for survival and growth. Biochemical and genomic analyses have indicated that Leishmania species express three potential routes for the synthesis of guanylate nucleotides: (1) a two-step pathway that converts IMP to GMP; (2) a three-step pathway that starts with the deamination of guanine to xanthine, followed by phosphoribosylation to XMP and then conversion to GMP; or (3) direct guanine phosphoribosylation by HGPRT. To determine the role of the first of these pathways to guanylate nucleotide synthesis, an L. donovani line deficient in IMP dehydrogenase (IMPDH), the first step in the IMP to GMP pathway, was constructed by targeted gene replacement. The Δimpdh lesion triggered a highly restrictive growth phenotype in promastigotes in culture but did not impact parasitemias in mice. The dispensability of IMPDH in vivo is the first definitive demonstration that intracellular L. donovani amastigotes have access to a sufficient pool of guanine, xanthine, or guanylate precursors from the host.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907738      PMCID: PMC3202435          DOI: 10.1016/j.molbiopara.2011.08.006

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  19 in total

Review 1.  Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery.

Authors:  Qingning Shu; Vasu Nair
Journal:  Med Res Rev       Date:  2008-03       Impact factor: 12.944

2.  Kinetic characterization of inosine monophosphate dehydrogenase of Leishmania donovani.

Authors:  Fredrick Dobie; Amanda Berg; Jan M Boitz; Armando Jardim
Journal:  Mol Biochem Parasitol       Date:  2006-12-05       Impact factor: 1.759

3.  Assessment of the Alamar Blue assay for cellular growth and viability in vitro.

Authors:  G R Nakayama; M C Caton; M P Nova; Z Parandoosh
Journal:  J Immunol Methods       Date:  1997-05-26       Impact factor: 2.303

Review 4.  Immunopathogenesis of infection with the visceralizing Leishmania species.

Authors:  Mary E Wilson; Selma M B Jeronimo; Richard D Pearson
Journal:  Microb Pathog       Date:  2005-04       Impact factor: 3.738

5.  Leishmania donovani singly deficient in HGPRT, APRT or XPRT are viable in vitro and within mammalian macrophages.

Authors:  Jan M Boitz; Buddy Ullman
Journal:  Mol Biochem Parasitol       Date:  2006-03-15       Impact factor: 1.759

6.  A conditional mutant deficient in hypoxanthine-guanine phosphoribosyltransferase and xanthine phosphoribosyltransferase validates the purine salvage pathway of Leishmania donovani.

Authors:  Jan M Boitz; Buddy Ullman
Journal:  J Biol Chem       Date:  2006-04-08       Impact factor: 5.157

7.  Amplification and molecular cloning of the IMP dehydrogenase gene of Leishmania donovani.

Authors:  K Wilson; F R Collart; E Huberman; J R Stringer; B Ullman
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

Review 8.  Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis.

Authors:  J J Marr
Journal:  J Lab Clin Med       Date:  1991-08

9.  Cloning and expression of the hypoxanthine-guanine phosphoribosyltransferase from Leishmania donovani.

Authors:  T E Allen; H Y Hwang; A Jardim; R Olafson; B Ullman
Journal:  Mol Biochem Parasitol       Date:  1995-07       Impact factor: 1.759

Review 10.  Mechanisms of action of ribavirin against distinct viruses.

Authors:  Jason D Graci; Craig E Cameron
Journal:  Rev Med Virol       Date:  2006 Jan-Feb       Impact factor: 6.989

View more
  6 in total

Review 1.  Purine salvage in Leishmania: complex or simple by design?

Authors:  Jan M Boitz; Buddy Ullman; Armando Jardim; Nicola S Carter
Journal:  Trends Parasitol       Date:  2012-06-20

Review 2.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

3.  Comprehensive proteomics analysis of glycosomes from Leishmania donovani.

Authors:  Mahendra D Jamdhade; Harsh Pawar; Sandip Chavan; Gajanan Sathe; P K Umasankar; Kiran N Mahale; Tanwi Dixit; Anil K Madugundu; T S Keshava Prasad; Harsha Gowda; Akhilesh Pandey; Milind S Patole
Journal:  OMICS       Date:  2015-03

4.  The cystathionine-β-synthase domains on the guanosine 5''-monophosphate reductase and inosine 5'-monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in response to guanylate and adenylate nucleotide levels.

Authors:  Sabrina Smith; Jan Boitz; Ehzilan Subramanian Chidambaram; Abhishek Chatterjee; Maria Ait-Tihyaty; Buddy Ullman; Armando Jardim
Journal:  Mol Microbiol       Date:  2016-03-10       Impact factor: 3.501

5.  GMP reductase and genetic uncoupling of adenylate and guanylate metabolism in Leishmania donovani parasites.

Authors:  Jan M Boitz; Armando Jardim; Buddy Ullman
Journal:  Mol Biochem Parasitol       Date:  2016-06-22       Impact factor: 1.759

Review 6.  Genetically modified organisms and visceral leishmaniasis.

Authors:  Rudra Chhajer; Nahid Ali
Journal:  Front Immunol       Date:  2014-05-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.